Scarless Laboratories
Scarless Laboratories is dedicated to promoting objectivity in research by establishing standards that ensure research funded under Public Health Service (PHS) grants or cooperative agreements is free from bias caused by Investigator financial conflicts of interest. The company adheres to strict policies for managing and disclosing financial interests to maintain integrity in research activities.
Industries
Nr. of Employees
small (1-50)
Scarless Laboratories
Beverly Hills, California, United States, North America
Products
Financial Conflict of Interest Policy document
Policy document describing definitions, disclosure requirements, management procedures, training expectations, reporting obligations, and recordkeeping for FCOI under federal regulations.
Significant Financial Interest (SFI) Disclosure Form (Form 001)
Standardized disclosure form for reporting significant financial interests and reimbursed travel, to be submitted annually and within 30 days of acquiring a new SFI.
Financial Conflict of Interest Policy document
Policy document describing definitions, disclosure requirements, management procedures, training expectations, reporting obligations, and recordkeeping for FCOI under federal regulations.
Significant Financial Interest (SFI) Disclosure Form (Form 001)
Standardized disclosure form for reporting significant financial interests and reimbursed travel, to be submitted annually and within 30 days of acquiring a new SFI.
Services
Creation and administration of an FCOI policy aligned with 42 CFR Part 50 Subpart F, including disclosure intake, review, management planning, enforcement, and federal reporting.
Mandatory investigator training on FCOI policy and NIH web-based tutorials with scheduled refresher training and event-triggered training when policy changes or noncompliance occurs.
Contractual inclusion of FCOI requirements for subrecipients, certification of equivalent policies, and timelines for subrecipient reporting to support prime institution reviews and federal reporting obligations.
Creation and administration of an FCOI policy aligned with 42 CFR Part 50 Subpart F, including disclosure intake, review, management planning, enforcement, and federal reporting.
Mandatory investigator training on FCOI policy and NIH web-based tutorials with scheduled refresher training and event-triggered training when policy changes or noncompliance occurs.
Contractual inclusion of FCOI requirements for subrecipients, certification of equivalent policies, and timelines for subrecipient reporting to support prime institution reviews and federal reporting obligations.
Expertise Areas
- Financial conflict of interest compliance
- Clinical trial design and conduct
- PHS/NIH grant administration
- Regulatory reporting to federal agencies
Key Technologies
- FCOI disclosure management workflows
- Regulatory reporting workflows for federal grants
- Clinical protocol development methodologies
- Retrospective review and mitigation procedures